Published in Psychopharmacology (Berl) on February 19, 2004
Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull (2007) 2.94
Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets (2006) 1.78
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull (2007) 1.45
Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol (2008) 1.32
The treatment of cognitive impairment in schizophrenia. Pharmacol Biochem Behav (2010) 1.16
Pharmacological characterization of the allosteric modulator desformylflustrabromine and its interaction with alpha4beta2 neuronal nicotinic acetylcholine receptor orthosteric ligands. J Pharmacol Exp Ther (2010) 1.11
Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. J Psychopharmacol (2014) 1.04
Paradoxical effects of prenatal acetylcholinesterase blockade on neuro-behavioral development and drug-induced stereotypies in reeler mutant mice. Psychopharmacology (Berl) (2006) 1.01
Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology (2005) 1.00
Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol (2007) 0.99
A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology (Berl) (2008) 0.99
Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Investig (2012) 0.98
Cholinergic modulation of cognitive processing: insights drawn from computational models. Front Behav Neurosci (2012) 0.98
Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method. Neuropharmacology (2011) 0.98
Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test. Behav Brain Res (2012) 0.97
Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology (2011) 0.95
Fine-tuning of awake prefrontal cortex neurons by clozapine: comparison with haloperidol and N-desmethylclozapine. Biol Psychiatry (2006) 0.94
Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. Psychopharmacology (Berl) (2009) 0.90
Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats. Neuropharmacology (2006) 0.90
Cholinergic connectivity: it's implications for psychiatric disorders. Front Cell Neurosci (2013) 0.89
Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) (2005) 0.88
Recent advances in treating cognitive impairment in schizophrenia. Psychopharmacology (Berl) (2008) 0.87
Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects. Eur Arch Psychiatry Clin Neurosci (2011) 0.86
Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berl) (2007) 0.84
Role of the central cholinergic system in the therapeutics of schizophrenia. Curr Neuropharmacol (2008) 0.84
Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice. Br J Pharmacol (2009) 0.84
Cholinergic modulation of auditory processing, sensory gating and novelty detection in human participants. Psychopharmacology (Berl) (2012) 0.84
Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence? Front Psychiatry (2013) 0.82
Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology (2009) 0.82
Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats. Psychopharmacology (Berl) (2013) 0.80
Why does the agonist [(18)F]FP-TZTP bind preferentially to the M(2) muscarinic receptor? Eur J Nucl Med Mol Imaging (2005) 0.80
Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation. Br J Pharmacol (2011) 0.77
An evaluation of the brain distribution of [(11)C]GSK1034702, a muscarinic-1 (M 1) positive allosteric modulator in the living human brain using positron emission tomography. EJNMMI Res (2014) 0.76
Axonal conduction block as a novel mechanism of prepulse inhibition. J Neurosci (2012) 0.75
The subchronic phencyclidine rat model: relevance for the assessment of novel therapeutics for cognitive impairment associated with schizophrenia. Psychopharmacology (Berl) (2015) 0.75
Effectiveness of rivastigmine on positive, negative, and cognitive symptoms of schizophrenia: a double-blind clinical trial. Ther Adv Psychopharmacol (2016) 0.75
Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine. Psychopharmacology (Berl) (2010) 0.75
Discovery of potential antipsychotic agents possessing pro-cognitive properties. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.75
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology (1998) 7.27
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA (1994) 5.98
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A (1997) 4.89
Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med (1998) 4.43
Muscarinic receptors--characterization, coupling and function. Pharmacol Ther (1993) 4.36
Prevalence of smoking among psychiatric outpatients. Am J Psychiatry (1986) 4.32
Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry (1994) 3.59
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology (2000) 2.99
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) (1996) 2.91
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci (1991) 2.73
Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry (1995) 2.72
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci (2003) 2.35
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol (1997) 2.35
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA (1994) 2.18
Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry (1993) 2.17
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry (2001) 2.04
Acetylcholine activates an alpha-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J Neurosci (1998) 1.99
Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther (2003) 1.77
Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology (2000) 1.77
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A (2001) 1.77
The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry (1996) 1.70
Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) (1998) 1.68
Essential role of neocortical acetylcholine in spatial memory. Nature (1995) 1.68
A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry (2002) 1.59
Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther (1992) 1.50
Upregulation of surface alpha4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J Neurosci (1999) 1.49
Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology (2002) 1.37
Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res (1992) 1.33
Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther (1998) 1.29
Human serial learning: enhancement with arecholine and choline impairment with scopolamine. Science (1978) 1.28
Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav (1997) 1.28
Postmortem studies in schizophrenia. Schizophr Bull (1998) 1.23
Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther (1999) 1.22
The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther (2001) 1.20
m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neurochem (1994) 1.19
Physostigmine: improvement of long-term memory processes in normal humans. Science (1978) 1.16
Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry (2001) 1.15
Comparative effects of cholinergic drugs and lesions of nucleus basalis or fimbria-fornix on delayed matching in rats. Psychopharmacology (Berl) (1985) 1.11
The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol (1986) 1.10
Attentional functions of the forebrain cholinergic systems: effects of intraventricular hemicholinium, physostigmine, basal forebrain lesions and intracortical grafts on a multiple-choice serial reaction time task. Exp Brain Res (1992) 1.10
Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol Pharmacol (1996) 1.10
Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry (2000) 1.09
Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther (1994) 1.09
Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry (2002) 1.07
Nucleus basalis magnocellularis and medial septal area lesions differentially impair temporal memory. J Neurosci (1987) 1.06
Desensitization of the nicotine-induced mesolimbic dopamine responses during constant infusion with nicotine. Br J Pharmacol (1995) 1.06
Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res (1989) 1.05
In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry (2003) 1.03
Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res (1995) 1.02
Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem (1995) 1.01
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology (2002) 1.00
Improvement in smooth pursuit eye movements after cigarette smoking in schizophrenic patients. Neuropsychopharmacology (1998) 0.99
Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine. Psychopharmacology (Berl) (1987) 0.98
Distributions of nicotinic acetylcholine receptor alpha7 and beta2 subunits on cultured hippocampal neurons. Neuroscience (1999) 0.94
The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. Neuropsychopharmacology (2003) 0.93
Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br J Pharmacol (1999) 0.91
Removal of the hippocampus and transection of the fornix produce comparable deficits on delayed non-matching to position by rats. Behav Brain Res (1992) 0.89
The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry (2001) 0.89
Recall memory deficit in schizophrenia. A possible manifestation of prefrontal dysfunction. Schizophr Res (1991) 0.88
Increased hippocampal acetylcholine release during a working memory task. Eur J Pharmacol (1996) 0.87
Memory and the septo-hippocampal cholinergic system in the rat. Psychopharmacology (Berl) (1983) 0.87
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia. Schizophr Res (2003) 0.87
Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes. Eur J Pharmacol (1989) 0.86
Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine. Eur J Clin Chem Clin Biochem (1991) 0.86
Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. Am J Psychiatry (1996) 0.83
Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors. Pharm Acta Helv (2000) 0.81
Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol (2003) 0.81
Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology (Berl) (1997) 0.81
Continuous ICV infusion of scopolamine impairs sustained attention of rhesus monkeys. Neurobiol Aging (1993) 0.80
Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study. Neurocase (2003) 0.80
Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci (1983) 0.80
Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies. Eur J Pharmacol (1994) 0.80
Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther (1994) 0.79
Differential competition with cytotoxic agents: an approach to selectivity in cancer chemotherapy. Science (1979) 0.78
The effects of AMPA-induced lesions of the septo-hippocampal cholinergic projection on aversive conditioning to explicit and contextual cues and spatial learning in the water maze. Eur J Neurosci (1995) 0.78
Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci (2001) 0.77
CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology. Pharm Acta Helv (2000) 0.76
Noncompetitive agonism at nicotinic acetylcholine receptors; functional significance for CNS signal transduction. J Recept Signal Transduct Res (1997) 0.76
Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin Neuropharmacol (1991) 0.76
Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers. J Pharmacol Exp Ther (1989) 0.75
(+/-)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine] hydrochloride, hemihydrate (SNI-2011, cevimeline hydrochloride) induces saliva and tear secretions in rats and mice: the role of muscarinic acetylcholine receptors. Jpn J Pharmacol (1998) 0.75
Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther (1999) 0.75
Deficits in passive-avoidance learning following atropine in the developing rat. Psychopharmacology (Berl) (1977) 0.75